An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study

Infect Dis (Lond). 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11.

Authors

Laura Galli¹, Andrea Poli¹, Camilla Muccini^{1

2}, Nadia Galizzi^{1

2}, Anna Danise¹, Vincenzo Spagnuolo², Nicola Gianotti¹, Elisabetta Carini¹, Adriano Lazzarin^{1

2}, Antonella Castagna^{1

2}

Affiliations

¹ a Infectious Diseases , IRCCS San Raffaele , Milano , Italy.
² b Università Vita-Salute San Raffaele , Milano , Italy.

PMID: 28891371
DOI: 10.1080/23744235.2017.1374552

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Anti-Retroviral Agents / administration & dosage
Anti-Retroviral Agents / therapeutic use*
Antiretroviral Therapy, Highly Active
Dideoxynucleosides / therapeutic use*
Drug Combinations
HIV Infections / drug therapy*
HIV-1 / drug effects
Humans
Lamivudine / therapeutic use*
Middle Aged
Raltegravir Potassium / therapeutic use*
Retrospective Studies
Treatment Outcome
Viral Load

Substances

Anti-Retroviral Agents
Dideoxynucleosides
Drug Combinations
abacavir, lamivudine drug combination
Lamivudine
Raltegravir Potassium